No Data
No Data
Hong Kong stocks have changed | Qunxin Biotech-B (02509) rose more than 3% and reached a strategic cooperation agreement with Huadong Medicine on QX005N injection.
Quanxin Biotech-B (02509) rose more than 3%, as of press time, up 3.48%, and reported 20.8 Hong Kong dollars, with a turnover of 1.0786 million Hong Kong dollars.
Up to 20% weight loss! Eli Lilly and Co's Theralogix (Tesofensine) approved in China, stronger effect than Sibutramine?
Is the competition intensifying?
Huadong Medicine's Unit Gets Joint Rights to Quanxin Bio's Anti-Inflammatory Drug
Quansheng Biotech-B (02509) has entered into a cooperation agreement with China-America East for the development and potential commercialization of QX005N.
Quanxin Biology-B (02509) announced that on July 19, 2024, the company reached a strategic cooperation with huadong medicine (its shares...
Express News | Huadong Medicine: Subsidiary Bohua Pharma acquires 100% equity of Hengba Pharma.
Express News | Galaxy Securities: The market size of global GLP-1 drugs is rapidly growing, recommended attention to domestic GLP-1 related symbols.
No Data